145 related articles for article (PubMed ID: 28988427)
1. Hydroxyurea therapy in UK children with sickle cell anaemia: A single-centre experience.
Phillips K; Healy L; Smith L; Keenan R
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28988427
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812
[TBL] [Abstract][Full Text] [Related]
3. Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience.
Youssry I; Abdel-Salam A; Ismail R; Bou-Fakhredin R; Mohamed Samy R; Ezz El-Deen F; Taher AT
Hemoglobin; 2017; 41(4-6):267-273. PubMed ID: 29251012
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of hydroxycarbamide in children with sickle cell disease - Analysis of dose-response metrics in a large birth cohort in a tertiary sickle cell centre.
Park H; Bhatti S; Chakravorty S
Pediatr Blood Cancer; 2019 Jul; 66(7):e27615. PubMed ID: 30666787
[TBL] [Abstract][Full Text] [Related]
5. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia.
Hankins JS; Aygun B; Nottage K; Thornburg C; Smeltzer MP; Ware RE; Wang WC
Medicine (Baltimore); 2014 Dec; 93(28):e215. PubMed ID: 25526439
[TBL] [Abstract][Full Text] [Related]
6. Intermittent or uneven daily administration of low-dose hydroxyurea is effective in treating children with sickle cell anemia in Angola.
Chambers TM; Kahan S; Camanda JF; Scheurer M; Airewele GE
Pediatr Blood Cancer; 2018 Dec; 65(12):e27365. PubMed ID: 30051651
[TBL] [Abstract][Full Text] [Related]
7. Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemia.
Nottage KA; Ware RE; Aygun B; Smeltzer M; Kang G; Moen J; Wang WC; Hankins JS; Helton KJ
Br J Haematol; 2016 Oct; 175(2):331-338. PubMed ID: 27604981
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
Sharef SW; Al-Hajri M; Beshlawi I; Al-Shahrabally A; Elshinawy M; Zachariah M; Mevada ST; Bashir W; Rawas A; Taqi A; Al-Lamki Z; Wali Y
Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171
[TBL] [Abstract][Full Text] [Related]
9. Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.
Inusa BPD; Wale A; Hassan AA; Idhate T; Dogara L; Ijei I; Qin Y; Anie K; Lawson JO; Hsu L
F1000Res; 2018; 7():. PubMed ID: 30228870
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea for the treatment of sickle cell disease.
el-Hazmi MA; Warsy AS; al-Momen A; Harakati M
Acta Haematol; 1992; 88(4):170-4. PubMed ID: 1292305
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey.
Colombatti R; Palazzi G; Masera N; Notarangelo LD; Bonetti E; Samperi P; Barone A; Perrotta S; Facchini E; Miano M; Del Vecchio GC; Guerzoni ME; Corti P; Menzato F; Cesaro S; Casale M; Rigano P; Forni GL; Russo G; Sainati L;
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28868627
[TBL] [Abstract][Full Text] [Related]
12. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease.
Gladwin MT; Shelhamer JH; Ognibene FP; Pease-Fye ME; Nichols JS; Link B; Patel DB; Jankowski MA; Pannell LK; Schechter AN; Rodgers GP
Br J Haematol; 2002 Feb; 116(2):436-44. PubMed ID: 11841449
[TBL] [Abstract][Full Text] [Related]
14. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea.
Hankins JS; Helton KJ; McCarville MB; Li CS; Wang WC; Ware RE
Pediatr Blood Cancer; 2008 Feb; 50(2):293-7. PubMed ID: 17554794
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness and acceptance of hydroxyurea in the treatment of severe forms of sickle cell disease: a prospective study of 65 cases].
Mellouli F; Chouaibi S; Dhouib N; Ouederni M; Ben Khaled M; Abbes S; Bejaoui M
Tunis Med; 2013; 91(8-9):544-50. PubMed ID: 24227514
[TBL] [Abstract][Full Text] [Related]
16. The effect of hydroxyurea on compound heterozygotes for sickle cell-hemoglobin D-Punjab--a single centre experience in eastern India.
Patel S; Purohit P; Mashon RS; Dehury S; Meher S; Sahoo S; Dash SS; Das K; Das P; Patel DK
Pediatr Blood Cancer; 2014 Aug; 61(8):1341-6. PubMed ID: 24616059
[TBL] [Abstract][Full Text] [Related]
17. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE
J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea in the treatment of sickle-cell anemia.
Howard LW; Kennedy LD
Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
[TBL] [Abstract][Full Text] [Related]
20. Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia.
Estepp JH; Winter B; Johnson M; Smeltzer MP; Howard SC; Hankins JS
Pediatr Blood Cancer; 2014 Nov; 61(11):2031-6. PubMed ID: 25132074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
